Skip to main content

Peer Review reports

From: Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors

Original Submission
15 Feb 2022 Submitted Original manuscript
19 Feb 2022 Author responded Author comments - Pei Zhang
Resubmission - Version 2
19 Feb 2022 Submitted Manuscript version 2
20 Mar 2022 Reviewed Reviewer Report
28 Mar 2022 Reviewed Reviewer Report
29 Jun 2022 Author responded Author comments - Pei Zhang
Resubmission - Version 3
29 Jun 2022 Submitted Manuscript version 3
29 Jul 2022 Reviewed Reviewer Report
25 Sep 2022 Author responded Author comments - Pei Zhang
Resubmission - Version 4
25 Sep 2022 Submitted Manuscript version 4
Publishing
8 Oct 2022 Editorially accepted
9 Nov 2022 Article published 10.1186/s12916-022-02598-5

You can find further information about peer review here.

Back to article page